Medical
Farhad Nalaini; Saleh Salehi Zahabi; Mohadese Abdoli; Elham Kazemi; Mahmood Mehrbakhsh; Salar Khaledian; Reza Fatahian
Abstract
In this review, we will discuss the neuroimaging findings of patients with COVID-19 from the outbreak (late December 2019) to the end of October 2021. PubMed, Scopus, Google Scholar, Science Direct, ProQuest, Web of Science and the World Health Organization database (January 01, 2020, to October 30, ...
Read More
In this review, we will discuss the neuroimaging findings of patients with COVID-19 from the outbreak (late December 2019) to the end of October 2021. PubMed, Scopus, Google Scholar, Science Direct, ProQuest, Web of Science and the World Health Organization database (January 01, 2020, to October 30, 2021) were searched for related published articles. In each of the databases, the appendix search strategies were performed and the below keywords were used: COVID-19”OR“coronavirus disease 2019” AND “brain MRI” OR “brain magnetic resonance imaging” OR “brain CT” OR “neuroimaging”. In total, neuroimaging findings of 1550 patients, with ages from 1-96 years, were analyzed. Most brain neuroimaging findings include hyperintensity, Cerebral venous thrombosis, intraventricular and subarachnoid hemorrhage, infarction, leukoencephalopathy, acute ischemic strokes and posterior reversible encephalopathy syndrome (PRES) in adult patients and severe encephalopathy, stroke, infarction, CNS infection/demyelination, neuritis or polyradiculitis, venous thrombosis, Guillain-Barré syndrome, and longitudinally extensive myelitis, and myositis in pediatric patients. Our findings showed that the most important complication of the coronavirus is not just respiratory complications, because although transiently, COVID-19-related brain complications are seen in pediatrics as well as adults, and families should pay more attention to health care.
Medical
Gandu Sravanthi; Kumara Swamy Gandla; Lalitha Repudi
Abstract
A new simple, selective, rapid, precise reversed-phase high-performance liquid chromatography method has been developed and validated for the estimation of Molnupiravir in bulk and its pharmaceutical dosage form. The separation was made using Symmetry ODS C18 (4.6×150mm, 5µm) column. The ...
Read More
A new simple, selective, rapid, precise reversed-phase high-performance liquid chromatography method has been developed and validated for the estimation of Molnupiravir in bulk and its pharmaceutical dosage form. The separation was made using Symmetry ODS C18 (4.6×150mm, 5µm) column. The mobile phase used contained Methanol. Phosphate Buffer pH-4.2 adjusted with Orthophosphoric acid solution in the ratio of 35:65% v/v in an isocratic mode at a wavelength of 236nm. The mobile-phase flow rate and the sample volume injected were 1 ml/min and 10 μL, respectively. The retention time of Molnupiravir was found to be 2.8 ±0.2mins. A good linear relationship of Molnupiravir r =0.999) was observed over a concentration range of 20 to 100µg/ml of Molnupiravir. The limit of detection (LOD) and limit of quantification (LOQ) for Molnupiravir was found to be 2.6µg/ml and 6.35µg/ml. The recovery percentage was observed in the range of 98-102%. The relative standard deviation for the precision study was found <2%. The developed method is simple, precise, specific, accurate and rapid, making it suitable for the estimation of Molnupiravir in bulk and marketed pharmaceutical dosage form. It was concluded that in the present developed RP- HPLC method is simple, rapid, and accurate, hence can be used for routine quality control analysis in the Pharmaceutical industry.
Medical
Mohammad Reza Mohammadi; Hoda Sabati
Abstract
NCP (new coronavirus pneumonia) was discovered in Wuhan towards the end of 2019 and quickly spread throughout the city. The infection was identified as a novel coronavirus, and the World Health Organization (WHO) called it coronavirus disease-19 (COVID-19). Most people with this infection can experience ...
Read More
NCP (new coronavirus pneumonia) was discovered in Wuhan towards the end of 2019 and quickly spread throughout the city. The infection was identified as a novel coronavirus, and the World Health Organization (WHO) called it coronavirus disease-19 (COVID-19). Most people with this infection can experience mild to severe and even fatal symptoms after a period of disease incubation of 4 to 14 days. In up to 10% of patients, gastrointestinal symptoms such as nausea and diarrhea, as well as associated abdominal discomfort, may occur before respiratory symptoms. Several SARS-CoV-2 variations have been identified during the epidemic, however, only a handful are deemed variants of concern (VOCs) by the WHO due to their worldwide public health effect. In this article, we looked at new mutations in COVID-19 as well as the adverse effects of the virus on the cardiovascular and gastrointestinal tract. The discovery of these novel SARS-CoV-2 variations threatens to undo the substantial success made so far in restricting the spread of this viral disease, despite the extraordinary speed with which vaccines against COVID-19 have been developed and vigorous worldwide mass immunization efforts. Through mechanisms involving the dysregulated ACE 2 receptor and TMPRSS2, the SARS-CoV-2 virus has the potential to induce significant systemic disease in the GI tract, liver, biliary tract, and pancreas. Due to the observation of new and daily mutations of this dangerous virus, the definitive treatment of this disease is becoming more and more difficult and facing major challenges that it requires many clinical trials and researches.
)
)
)